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Abstract The purpose of this study was to investigate the
effects of arsenic trioxide (As2O3) on the infiltration of regu-
latory T cells (Tregs) in the local lung metastasis of mouse
colon cancer in vivo and the regulation of Tregs in cytokine-
induced killer cells (CIKs) in vitro. A high Tregs infiltration
mouse colon cancer lung metastasis model was established by
intravenous injection of CT26 murine colon carcinoma cells.
Tumor-bearing mice were randomly divided into three
groups: control group, low-dose As2O3 group, and high-
dose As2O3 group. For in vitro studies, CIKs were treated with
vehicle control or 0.1, 1, or 5 μM As2O3. The level of Tregs
was detected via flow cytometry, Foxp3 expression was
assessed by immunohistochemistry and reverse transcrip-
tion–polymerase chain reaction (RT-PCR), the level of inter-
feron gamma (IFN-γ) was evaluated by enzyme-linked im-
munoassay (ELISA), and the cytotoxic activity of As2O3-
treated CIKs was assessed through a lactate dehydrogenase
(LDH) release assay. Obvious lung metastasis was observed
3 days after CT26 murine colon carcinoma cell injection. The
numbers of Tregs in the lungs and spleens of tumor-bearing
mice were significantly higher than those of the normal group
(p < 0.01). As2O3 treatment increased the mouse weight as
well as reduced the number of metastatic lung nodules and the
lung/body weight ratio (p < 0.01). Moreover, As2O3 treatment
significantly reduced the Tregs proportion and the Foxp3mes-
senger RNA (mRNA) levels in metastatic lung tissues
(p < 0.01). In vitro, As2O3 significantly reduced the Tregs
proportion and the Foxp3 mRNA levels (p < 0.01) and signif-
icantly increased the cytotoxic activity of CIKs and the IFN-γ
levels in the supernatant of cultured CIKs (p < 0.01). As2O3
might inhibit lung metastasis of colon cancer by reducing the
local infiltration of Tregs and increase the cytotoxic activity of
CIKs by suppressing Tregs.
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Introduction
Arsenic trioxide (As2O3) has been applied for the treatment of
acute lymphoblastic leukemia. Emerging evidence has sug-
gested that As2O3 has a therapeutic effect in many solid tu-
mors by inducing apoptosis and inhibiting the invasion and
migration of tumor cells [1–4]. Despite a limited anti-tumor
effect of As2O3 monotherapy, it can enhance the anti-tumor
effects of metformin [5] and sorafenib [6]. It has been well
documented that immunity plays a key role in cancer therapy
response [7]. Some studies have found that As2O3 can modu-
late the body’s immune response via CD4+ T/CD8+ T cells [8,
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The number of regulatory T cells (Tregs) is highly in-
creased in cancer patients, and Tregs promote tumorigen-
esis by reducing the number of T helper cells [10]. In
addition, a high proportion of Tregs is one of the bottle-
necks that affect the efficacy of adoptive immunotherapy
[11]. Therefore, reducing the number of Tregs has become
a critical issue for successful tumor immunotherapy.
Cyclophosphamide, CD25 monoclonal antibodies, and
cytotoxic T lymphocyte-associated protein 4 monoclonal
antibodies have been shown to reduce the number of
Tregs [12], but these drugs only transiently reduce the
number of Tregs [13]. Hernandez et al. first reported that
As2O3 could increase the Treg ratio in the spleen of my-
elitis rats [14]. Subsequently, Thomas et al. found that
As2O3 reduced the proportion of Tregs in the spleen of
a colon cancer subcutaneous rat model [15]. These find-
ings suggest that As2O3 may act as a sensitizer of other
therapeutic modules by reducing the number of Tregs.
However, the molecular pharmacology of suppression of
Tregs by As2O3 and whether As2O3 can reduce Tregs
infiltration in the local metastatic tumor tissues remain
to be determined.
In clinical practice, some colorectal cancer patients have
lung metastases at diagnosis; moreover, lung metastasis
also frequently occurs in colorectal cancer patients
postoperation. It has been found that significantly
increased numbers of tumor-infiltrating Tregs are seen in
lung metastasis models of colon cancer as well as an
increased proportion of Tregs in cytokine-induced killer
cells (CIKs), so in this study, we investigated the effects
of As2O3 on the infiltration of Tregs in local lung metasta-
sis of mouse colon cancer in vivo and the regulation of
Tregs in CIKs in vitro.
Materials and methods
Reagents and cell lines
As2O3 was purchased from Sigma (St. Louis, MO, USA)
and stored at 4 °C. Human colon cancer SW-620 cells and
mouse colon cancer CT26 cells were obtained from the
Institute of General Surgery, Chinese PLA General
Hospital (Beijing, China), and cultured in RPMI 1640
medium (Gibco, Grand Island, NY, USA), supplemented
with 10 % inactivated fetal bovine serum (Gibco, Grand
Island, NY, USA), 100 U/mL penicillin, and 100 μg/mL
streptomycin at 37 °C in a 5 % CO2 incubator (Thermo
Scientific, Waltham, MA, USA). Bouin’s solution was
prepared by mixing 75 mL of saturated picric acid
(Beijing Taiyu Tiangong Biotechnology, Beijing, China),
25 mL of 40 % formaldehyde, and 5 mL of acetic acid.
Animal models and in vivo experiments
BALB/c female mice of 6–8 weeks old were purchased
from the Beijing Experimental Animal Center of the
Academy of Military Medical Sciences (Beijing,
China). A total of 1 × 105 mouse CT26 cells in
100 μL of phosphate-buffered saline (PBS) were slowly
injected into mice through the tail vein to establish the
mouse lung metastasis model of colon cancer. Three
days after injection, tumor-bearing mice were randomly
divided into three groups: control group (treated with
saline, i.v.), low-dose group (treated with As2O3 at
3 mg/kg/day, i.v.), and high-dose group (treated with
As2O3 at 6 mg/kg every other day, i.v.), and the treat-
ment continued for 2 weeks. The weight of the mice
was recorded every day. When the experiment was
terminated, a mononuclear cell suspension was prepared
from eyeball blood. Then, the lungs were removed with
a sterile technique to calculate the lung/body weight
ratio, and enriched lymphocytes were prepared from
the left lungs (described below). A mononuclear cell
suspension was prepared by grinding the spleen tissue.
Aliquots of the peripheral blood, spleen fluid, and lung
metastasis lymphocytes were analyzed by flow cytome-
try to determine the proportion of Tregs. Parts of the
right lobe of the lungs were processed for hematoxylin
and eosin (HE) staining, immunohistochemical staining
of Foxp3, and reverse transcription–polymerase chain
reaction (RT-PCR) analysis of Foxp3 messenger
RNA (mRNA). Another batch of mice was used to
evaluate the effects of As2O3 on the survival of the
CT26 mice.
Count of metastatic lung nodules
Lung tissues were first fixed and stained with Bouin’s
solution, and then the metastatic lung nodules were
classified under a microscope as described previously
[16]. Metastatic nodule diameters of less than 0.5,
0.5–1, 1–2, and greater than 2 mm were classified as
grade I, II, III, and IV metastasis, respectively. Then,
the total number of metastases was calculated according
to the following formula: total metastasis number = (grade
I metastasis number) + (grade II metastasis number × 2) +
(grade III metastasis number × 3) + (grade IV metastases
number × 4).
Enrichment of lymphocytes from lung tissues
The lungs were flushed three times with PBS in order to
wipe off the lymphocytes resided in the branchial alveolus.
Next, using sterile techniques, the left lung was removed,
cut into pieces, and digested with collagenase II (Gibco,
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Grand Island, NY, USA), Dnase I (Gibco, Grand Island,
NY, USA), and hyaluronic acid enzyme V (Sigma-
Aldrich, St. Louis, MO, USA) for 3 h with magnetic
stirring at room temperature. The mononuclear cell suspen-
sion was prepared by centrifugation (Eppendorf Minispin,
Hamburg, Germany) and filtration, followed by discontin-
uous density gradient centrifugation with mouse lympho-
cyte separation medium (MP Biomedicals, Santa Ana, CA,
USA). The lower layer of the cell suspension that was rich
in lymphocytes was collected.
HE staining and immunohistochemistry
The right lung was fixed with formalin, embedded in paraffin,
and sliced into 4-μm sections. HE staining was performed to
check for necrosis of the tumor cells. Infiltrating Foxp3+ Tregs
in the local lung metastasis were analyzed by immunohisto-
chemistry. Elivision immunohistochemistry was performed
using the standard streptavidin peroxidase complex technique
on 4-μm-thick paraffin-embedded tissue sections. After pre-
treatment and blocking, Foxp3 immunostaining was per-
formed using a rabbit anti-mouse Foxp3 monoclonal antibody
(Abcam, Cambridge, UK) as the primary antibody and
streptavidin-biotinylated anti-rabbit immunoglobulin G as
the secondary antibody. This procedure was followed by in-
cubation with a streptavidin-horseradish peroxidase enzyme
conjugate. The sections were visualized using 3,3′-diamino-
benzidine and finally counterstained with hematoxylin.
Negative controls were subjected to immunohistochemistry
by replacing the primary antibody with PBS solution.
Foxp3+ cells were stained tan or brown. The number of
Foxp3+ cells in five random fields was counted under a light
microscope at high magnification (×400, Olympus BX53,
Japan). The average number of cells from five fields was de-
fined as the number of Tregs.
Preparation of human CIKs for in vitro experiments
Amononuclear cell suspension from 20 mL of healthy human
peripheral blood was prepared by density gradient centrifuga-
tion with human lymphocyte separation medium (Chinese
Academy of Medical Sciences, Beijing, China). After incuba-
tion for 3 h, the nonadherent floating cells were collected and
cultured in 75-mm T-type flasks with 10 mL of Cellix 601
serum-free medium (Beijing Xin Ming Thai Biotechnology,
Beijing, China) supplemented with 1000 U/mL recombinant
human interferon gamma (IFN-γ) (R&D, MN, USA) at 37 °C
in a humidified incubator containing 5 % CO2 for 24 h. The
next day, 2 μg/mL anti-CD3 McAb (BD, NJ, USA) and
1000 U/mL recombinant human interleukin-2 (IL-2) (R&D,
MN, USA) were added to the medium. Twenty-four hours
later, the medium was replaced with fresh medium containing
1000 U/mL recombinant human IL-2. On day 5, the medium
was replaced with Cellix 602 serum-free medium, and the
cells were cultured in a 1000-mL culture bag. The cell status
was frequently monitored, and media and recombinant human
IL-2 were supplemented at appropriate times. The CIKs were
harvested on day 14. For the in vitro studies, 2 × 107 CIKs in a
100-mm dish were treated with vehicle control or 0.1, 1, or
5 μM As2O3 for 48 h. Then, the experiments were repeated
three times in vitro. The ratio of CD4+ CD25+ Foxp3+ Tregs
or CD4+/CD8+ T cells in the CIKs was determined by flow
cytometry. The expression of Foxp3 in the CIKs was detected
by RT-PCR. Enzyme-linked immunoassay (ELISA) was used
to detect the content of IFN-γ in the cell culture supernatant. A
lactate dehydrogenase (LDH) release assay was used to assess
the cytotoxic activity of the CIKs.
Flow cytometric detection of Tregs
The prepared CIKs were first incubated with CD4 FITC (BD,
NJ, USA) and CD25APC (BD, NJ, USA), followed by per-
meabilization and staining with Foxp3-percp antibody (BD,
NJ, USA), according to the manufacturer’s protocol. All sam-
ples were examined using a FACSCalibur instrument (BD,
NJ, USA), and the data were analyzed using FlowJo 7.6.1
software.
Cytotoxicity assay
The in vitro cytotoxicity of CIKs to SW-620 cells was performed
by an LDH release assay (Sigma-Aldrich, St. Louis, MO, USA),
as described previously [17]. The target SW-620 cells were
mixed with CIKs treated with different concentrations of
As2O3 at a ratio of 5:1 or 10:1 and cultured for 24 h. The optical
density (OD) value was detected with a microplate reader at a
wavelength of 492 nm. The killing rate was calculated as fol-
lows: Cytotoxicity % = [OD(Experimental) − OD(Effector
spontaneous) − OD(Target spontaneous)] × 100 / [OD(Target
maximum) − OD(Target spontaneous)].
ELISA detection of cytokines
CIKs were treated with different concentrations of As2O3 for
48 h. The IFN-γ content in the supernatant was determined
using an IFN-γ ELISA kit (Sigma-Aldrich, St. Louis, MO,
USA), according to the manufacturer’s protocol. The OD val-
ue was detected with a microplate reader at a wavelength of
492 nm.
RT-PCR detection of Foxp3
Mouse and human Foxp3 as well as β-actin primers were
designed and synthesized by Shanghai Sangon (Shanghai,
China). The sequences of the primers were as follows: mouse
β-actin primer sequences, M-β-actin-F: 5ʹ-GTGCTATG
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TTGCTCTAGACTTCG-3ʹ; M-βactin-R: 5ʹ- ATGCCACA
GGATTCCATACC-3ʹ; mouse Foxp3 primer sequence,
M-Foxp3-F: 5ʹ-TGGTTTACTCGCATGTTCGC-3ʹ, M-
Foxp3-R: 5ʹ-CCCACCTTTTCTTGGTTTTGA-3ʹ’ human
β-actin primer sequences, H-β-actin-F: 5ʹ-TAGTTGCG
TTACACCCTTTCTTG-3ʹ, H-β-actin-R: 5ʹ-TCACCTTC
ACCGTTCCAGTTT-3ʹ; human Foxp3 primer sequence, H-
Foxp3-F: 5ʹ-AGGAAAGGAGGATGGACGAA-3ʹ, H-
Foxp3-R: 5ʹ-GCAGGCAAGACAGTGGAAAC-3ʹ. The
lungs were flushed three times with PBS, and then the homog-
enates were prepared by rapidly grinding the frozen tissues in
liquid nitrogen. ATO-treated CIKs were washed three times
and resuspended at 1.0 × 107/mL. Total RNA was extracted
using TRIzol reagent (Life Technologies, Rockville, MD,
USA), according to the manufacturer’s instructions. The
amount of total RNAwas determined by measuring the absor-
bance at 260 nm with a spectrophotometer. One microgram of
total RNA was reverse-transcribed to the complementary
DNA (cDNA) using the PrimeScript 1st Strand cDNA
Synthesis Kit (Takara, Dalian, China), according to the man-
ufacturer’s protocol. Real-time PCR was conducted by the
SYBR Green method on a Corbett Rotor-Gene 3000
(Corbett Research, Concorde, Australia) real-time thermal cy-
cler. Data were expressed using the comparative threshold
cycle method and normalized to the housekeeping gene β-
actin.
Statistical analysis
SPSS 21.0 statistical software was used for statistical analysis
of the relevant data. Data are expressed as the mean ± standard
deviation. Differences between two groups were compared
using the t test. Differences among several groups were ana-
lyzed using one-way analysis of variance. The Kaplan-Meier
test was performed for survival analysis. P < 0.05 was con-
sidered statistically significant.
Results
Establishment of the mouse colon cancer lung metastasis
model with high Treg infiltration
BALB/cmicewere randomly divided into two groups: normal
group and model group. Metastatic lung nodules appeared
3 days after intravenous injection of CT26 cells (Fig. 1a).
The number and volume of nodules gradually increased and
fused with time (Fig. 1b). A significantly higher number of
infiltrating Tregs in the model group was detected compared
with that of normal group (p < 0.01, Fig. 1b). Moreover, the
number of infiltrating Tregs in the spleen of the model group
was also significantly higher than that of the normal group
(p < 0.01, Fig. 1c). However, there was no significant
difference in the number of infiltrating Tregs in the peripheral
blood between model group and normal group (Fig. 1c).
As2O3 inhibited lung metastasis of mouse colon cancer
Three days after the injection of CT26 cells, tumor-bearing
mice were randomly divided into three groups: control group
(treated with saline, i.v.), low-dose group (treated with As2O3
at 3 mg/kg/day, i.v.), and high-dose group (treated with As2O3
at 6 mg/kg every other day, i.v.). After As2O3 treatment, the
mouse body weight increased significantly, with the most ob-
vious effect in the high-dose group (p < 0.01). However, there
was no significant difference of body weight between these
two treatment groups (Fig. 2a). Physical analysis showed that
both the lung volume and the number of metastatic lung nod-
ules were decreased after As2O3 treatment (Fig. 2b). HE stain-
ing demonstrated increased tumor cell debris and tumor inter-
stitial fibrosis in the As2O3 treatment groups, compared with
the control group (Fig. 2c). Quantitative analysis showed that
As2O3 treatment significantly reduced the number of metasta-
tic lung nodules (Fig. 2d) and the lung/body weight ratio
(Fig. 2e) (p < 0.01). The survival times of mice in the low-
and high-dose As2O3 groups were significantly prolonged
(p < 0.01, Fig. 2f), and the survival rates were 37.5 and
50 % at 40 days after CT26 injection, respectively (Fig. 2f).
As2O3 reduced the infiltration of Tregs and suppressed
the expression of Foxp3 in lung metastases of colon cancer
in mice
To test whether As2O3 reduces the infiltration of Tregs, the
Treg ratios in the lung, spleen, and peripheral blood were
assessed by flow cytometry. The results showed that both
the low and high doses of As2O3 could significantly reduce
the number of infiltrating Tregs in lung metastases, with a
greater inhibitory effect by the low dose (p < 0.01, Fig. 3a).
The high dose but not the low dose of As2O3 significantly
reduced the number of infiltrating Tregs in the spleen
(p < 0.01, Fig. 3a). Neither the low dose nor the high dose
of As2O3 reduced the number of infiltrating Tregs in the pe-
ripheral blood (Fig. 3a). We determined the expression of
Foxp3 in the lung by RT-PCR and immunohistochemistry.
Immunohistochemical analysis showed lots of dark brown
Foxp3+-stained cells in the lung tissues before treatment,
while in the low-dose and the high-dose As2O3 groups, obvi-
ously reduced numbers of Foxp3+-stained cells in the lung
were seen (Fig. 3b). Further semiquantitative analysis demon-
strated that As2O3 treatment significantly decreased the num-
ber of Foxp3+ cells in the lung tissues (p < 0.01, Fig. 3c), but
there was no significant difference between these two treat-
ment groups (Fig. 3c). RT-PCR results showed the same trend,
in which As2O3 treatment significantly decreased Foxp3
mRNA expression in the lung tissues (p < 0.01, Fig. 3d),
15168 Tumor Biol. (2016) 37:15165–15173
and there was no significant difference between these two
treatment groups (Fig. 3d).
As2O3 dose-dependently decreased the percentage
of Tregs in CIKs and improved the cytotoxic activity
of CIKs in vitro
To extend our in vivo observation and explore the
potential pharmacology of As2O3 in reducing the tumor
burden of the mouse colon cancer, we treated CIKs with
different concentrations of As2O3 for 48 h. The expres-
sion of CD25 and Foxp3 was double-stained in the
pooled CD4+ T cells (Fig. 4a). The flow cytometry
results showed that As2O3 treatment significantly
decreased the percentage of CD4+ T cells, with a greater
effect by 1 μM As2O3 (p < 0.01, Fig. 4b). As2O3 treat-
ment significantly decreased the ratio of Tregs, with a
greater effect by 5 μM As2O3 (p < 0.01, Fig. 4c).
Further studies showed that the expression of Foxp3 in
the pooled CD4+ T cells was reduced in a dose-
dependent manner (p < 0.01, Fig. 4d), which was
confirmed with respect to the Foxp3 mRNA levels by
RT-PCR (p < 0.01, Fig. 4e).
The cytotoxic activity of As2O3-treated CIKs was evaluat-
ed through different ways in vitro. First, the percentage of
CD8+ T cells increased according to the different concentra-
tions of As2O3, with a greater effect by 5 μMAs2O3 (p < 0.05,
Fig. 4f). Second, ELISA analysis detected a significant in-
crease of IFN-γ levels in the CIK supernatants of the
As2O3-treated groups (p < 0.01, Fig. 4g). Finally, we deter-
mined the in vitro cytotoxicity of CIKs toward SW-620 cells
by the LDH release assay. The target SW-620 cells were
mixed with As2O3-treated CIKs at a ratio of 5:1 or 10:1, and
the cells were cultured for 24 h. The results showed that As2O3
treatment significantly improved the cytotoxic activity of
CIKs (p < 0.01, Fig. 4h).
Fig. 1 Establishment of the mouse colon cancer lung metastasis model
with high Treg infiltration. Metastatic lung nodules appeared 3 days after
intravenous injection of CT26 cells (a). The number and volume of
nodules gradually increased and fused with time on days 0, 3, 8, and 15
(b). A significantly higher number of infiltrating Tregs in the lung and
spleen of the model group was detected compared with that of the normal
group (p < 0.01, C). However, there was no significant difference in the
number of infiltrating Tregs in the peripheral blood between the model
group and the normal group (c) (**p < 0.01, n = 6 per group)
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Discussion
In this study, we demonstrated that As2O3 potently
decreased the tumor burden and inhibited the lung me-
tastasis of colon cancer in a mouse model. Importantly,
we showed that As2O3 reduced the infiltration of Tregs
and suppressed the expression of Foxp3 in lung metas-
tases of colon cancer. In vitro, As2O3 significantly
improved the cytotoxic activity of CIKs, accompanied
with a decreased percentage of CD4+CD25+Foxp3+
Tregs in CIKs.
In the lung metastasis model of mouse colon cancer
established in this study, lung metastasis appeared very early,
with significant infiltration of Tregs/CD3 in the lung but not in
the peripheral blood, suggesting an ideal model for the study
of pharmacological inhibition of Tregs in the treatment of
colon cancer. With this model, we found that As2O3 signifi-
cantly inhibited the pulmonary metastasis of colon cancer,
without significant toxicity. As2O3-treated mice displayed a
significantly increased body weight and reduced the tumor
burden and the number of metastatic lung nodules.
However, no significant difference was observed between
the low and high doses of As2O3. It has been reported that
6.5 mg/kg As2O3 is selectively enriched in tumor tissues rath-
er than in the liver, brain, kidney, and other tissues and does
not cause significant toxicity [18]. However, we found that in
the first administration, high-dose As2O3 (6.0 mg/kg) induced
transient acute toxicity in mice, which lasted for 10 min and
returned to normal after 30 min (data not shown), suggesting
that As2O3 toxicity in the first dosing should be noted.
Moreover, As2O3 has been shown to induce tumor cell toler-
ance [19] and cumulative toxic effects [20], which may ex-
plain the similar effects of the low-dose and high-dose As2O3
treatment. Compared with 5-fluorouracil, As2O3 does not
cause deterioration of the nutritional status of tumor-bearing
mice [21]. Therefore, these facts suggest that As2O3 might be
Fig. 2 As2O3 inhibited lung metastasis of mouse colon cancer. After
As2O3 treatment for 2 weeks, the mouse body weight increased
significantly, with the most obvious effect in the high-dose group
(p < 0.01); however, there was no significant difference of body weight
between these two treatment groups (a). Physical analysis showed that
both the lung volume and the number of metastatic lung nodules were
decreased after As2O3 treatment (b). HE staining demonstrated increased
tumor cell debris and tumor interstitial fibrosis in the As2O3 treatment
groups, compared with the control group. The blue arrows represent cell
debris, and the red arrow represents fibrosis (c). Quantitative analysis
showed that As2O3 treatment significantly reduced the number of
metastatic lung nodules (d) and the lung/body weight ratio (e), compared
with the control group (**p < 0.01, n = 6 per group). The survival times of
mice in the low- and high-dose groups were prolonged significantly
(**p < 0.01, f), and the survival rates were 37.5 and 50 % at 40 days after
CT26 injection, respectively (n = 8 per group, f)
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more effective than 5-fluorouracil for the treatment of lung
metastasis in colon cancer.
Previous studies have shown that Tregs are selectively
enriched in colon tumor sites and play a key role in tumor
immune escape [22–24]. In addition, a high concentration of
local tumor-infiltrating Tregs is the most crucial factor affect-
ing the prognosis of patients with colon cancer [25–27]. Thus,
reducing the number of local tumor-infiltrating Tregs may be
of more clinical significance. Our in vivo study showed that
As2O3 could significantly reduce local infiltration of Tregs
and Foxp3 expression, which suggested that As2O3 inhibited
lung metastasis of colon cancer via selectively reducing the
infiltration of Tregs. In vitro, As2O3 not only selectively re-
duced the proportion of Tregs in CIKs but also increased the
cytotoxic activity of CIKs, as demonstrated by the higher pro-
portion of CD8+ T cells and the increased IFN-γ levels.
Moreover, we found that As2O3 reduced the amount of CD4
+ T cells, which was consistent with the previous reports [28,
29]. Taken together, As2O3 might inhibit lymphocyte prolif-
eration largely through selective inhibition of CD4+ T cells,
thereby increasing the CD8+ Tcell ratio. Therefore, the appro-
priate dose of As2O3 might be used as an immune adjuvant to
provide an improved treatment outcome for colon cancer.
The mechanism by which As2O3 reduces Tregs is unclear
now. In this study, we found that the order of reduction of
Foxp3 expression by As2O3 was high dose, medium dose,
and low dose; the order of reduction of CD4+ T cells by
As2O3 was medium dose, high dose, and low dose, which
Fig. 3 As2O3 reduced the infiltration of Tregs in lung metastases of
mouse colon cancer. The flow cytometry results showed that both the
low dose and the high dose of As2O3 significantly reduced the number
of infiltrating Tregs in lung metastases, with a greater inhibitory effect by
the low dose (p < 0.01, a). The high dose but not the low dose of As2O3
significantly reduced the number of infiltrating Tregs in the spleen
(p < 0.01, a). Neither the low nor the high dose of As2O3 reduced
the number of infiltrating Tregs in the peripheral blood (a).
Immunohistochemical analysis showed lots of dark brown Foxp3+
staining in lung tissues before treatment, while in the low dose and
the high dose of As2O3 groups, obviously reduced numbers of
Foxp3+-stained cells in the lung were seen (b). Further semiquantitative
analysis demonstrated that As2O3 treatment significantly decreased the
number of Foxp3+ cells in the lung tissues (p < 0.01, c), but there was no
significant difference between these two treatment groups (c). RT-PCR
results showed the same trend, in which As2O3 treatment significantly
decreased Foxp3 mRNA expression in the lung tissues (p < 0.01, d), and
there was no significant difference between these two treatment groups
(d). (**p < 0.01, n = 6 per group)
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means that different concentrations of As2O3 reduce Tregs via
different mechanisms: the medium concentration might main-
ly be via decreasing the proportion of CD4+ T cells, while the
high concentration might mainly be through reducing Foxp3
expression. Furthermore, the detailed mechanisms need to be
explored in the future.
In summary, we demonstrated that As2O3 might inhibit
lung metastasis of colon cancer by reducing the local infiltra-
tion of Tregs and increase the cytotoxic activity of CIKs by
suppressing Tregs.
Acknowledgments This study was supported by the Dalian Municipal
Science and Technology project (2012J21DW012); the Liaoning
Provincial Department of Education Science Research general project
(L2014345); and the Natural Science Fund Project of the Department of
Science and Technology of Liaoning Province (2015020306).
Compliance with ethical standards Written informed consents were
obtained from the patients and healthy donors. This study was approved
by the Ethics Committee of The First Affiliated Hospital of Dalian
Medical University (reference number KY2014-05). The experimental
mice used in this study were obtained from the Laboratory Animal
Center of the Academy of Military Medical Science. All experimental
procedures and postoperative animal care were conducted according to
the protocols approved by the Animal Care and Use Committee of
Chinese PLA General Hospital and the National Institute of Health’s
Guidelines for the Care and Use of Laboratory Animals.
Conflicts of interest None
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
Fig. 4 As2O3 reduced the Treg ratio in CIKs and improved the cytotoxic
activity of CIKs in vitro. The expression of CD25 and Foxp3 was double-
stained in the pooled CD4+ Tcells after membranes rupture (a). The flow
cytometry results showed that As2O3 treatment significantly decreased
the percentage of CD4+ T cells, with a greater effect by 1 μM As2O3
(p < 0.01, b). As2O3 treatment significantly decreased the ratio of Tregs,
with a greater effect by 5 μM As2O3 (p < 0.01, c). The expression of
Foxp3 in the pooled CD4+ T cells was reduced in a dose-dependent
manner (p < 0.01, d), which was confirmed with respect to the Foxp3
mRNA levels by RT-PCR (p < 0.01, e). The cytotoxic activity of As2O3-
treated CIKs was evaluated through different ways in vitro. The ratio of
CD8+ T cells increased significantly by treatment with 5 μM As2O3
(p < 0.05, f), and the level of IFN-γ harvested from the supernatant of
CIKs increased significantly, with a greater effect by 1 μM As2O3
(p < 0.01, g). As2O3 treatment significantly improved the cytotoxic
activity of CIKs at a ratio of 5:1 or 10:1 SW-620 cells to CIKs
(p < 0.01, h) (# compared with the control group, #p < 0.05, ##p < 0.01;
*compared between the experimental groups, *p < 0.05, **p < 0.01. The
in vitro experiments were repeated three times)
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